Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center
- 28 Downloads
Serum vascular endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that is considered a valuable tool in the diagnosis of lymphangioleiomyomatosis (LAM). Previous studies have reported a wide variability in VEGF-D serum levels in LAM patients and it seems to be associated with pulmonary impairment and lymphatic involvement.
We conducted a cross-sectional study from 2009 to 2017 that evaluated VEGF-D serum levels in a cohort of LAM patients who were never treated with mTOR inhibitors and compared them to healthy age-matched volunteers. Clinical and functional parameters were assessed and correlated with their respective serum VEGF-D levels.
One hundred and four patients were included in the analysis. Serum VEGF-D levels were higher in LAM patients compared to healthy controls: 796 (404–1588) versus 162 (117–232) pg/mL, respectively (p < 0.001). Patients with tuberous sclerosis complex–LAM, TSC–LAM (20%), had higher levels of VEGF-D when compared to patients with sporadic LAM (80%) [1005 (641–2732) vs. 772 (370–1383), p = 0.05]. Serum VEGF-D levels were weakly correlated with DLCO (r = − 0.26, p = 0.001) and lymphatic involvement was more frequent in those with serum VEGF-D levels equal or above 800 pg/mL (35% vs. 13%, p = 0.02).
In LAM, serum VEGF-D is weakly associated with lung function impairment and strongly associated with lymphatic involvement. VEGF-D is validated for use in Brazilian patients with LAM whose characteristics must be accounted for when evaluating their serum VEGF-D levels.
KeywordsInterstitial lung disease Lymphangioleiomyomatosis Pulmonary function tests Vascular endothelial growth factor
Other members of the Tuberous Sclerosis, Lymphangioleiomyomatosis and Angiomyolipoma Study Group include the following: Bruno Eduardo Pedroso Balbo, Elieser Hitoshi Watanabe, Luciana Paula Samorano, Luiz Fernando Onuchic, Maria Cecília da Matta Rivitti-Machado, Maria Luiza Giraldes de Manreza, Maurício Dener Cordeiro, Patrícia Takahashi, and Zilda Najjar Prado de Oliveira.
Financial support for this study was provided by Novartis Biociências S.A. Novartis had no participation whatsoever in the design, management, and analysis of data or in the decision to publish this study.
Compliance with Ethical Standards
Conflict of interest
The authors received no refunds or financial benefits and have no conflicts of interest to declare.
- 5.Baldi BG, Salim C, Freitas G, Araujo MS, Dias OM, Pereira DAS et al (2014) Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffus Lung Dis 31(2):129–135Google Scholar
- 10.Radzikowska E, Jagus P, Skoczylas A, Sobiecka M, Chorostowska-Wynimko J, Wiatr E et al (2013) Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn 123(10):533–538Google Scholar
- 16.Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C et al (2013) Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 1(6):445–452CrossRefGoogle Scholar
- 26.Pereira CA, Sato T, Rodrigues SC (2007) New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol publicaça̋o Of da Soc Bras Pneumol e Tisilogia 33(4):397–406Google Scholar
- 28.Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR et al (2017) Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 196(10):1337–1348CrossRefGoogle Scholar